| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial
|
Tyagi, Preeta
|
|
2006
|
6 |
4 |
p. 261-264
4 p.
|
artikel
|
| 2 |
Gene Expression Levels of Epidermal Growth Factor Receptor, Survivin, and Vascular Endothelial Growth Factor as Molecular Markers of Lymph Node Involvement in Patients with Locally Advanced Rectal Cancer
|
Yang, Dongyun
|
|
2006
|
6 |
4 |
p. 305-311
7 p.
|
artikel
|
| 3 |
Highlights from: Fifth International Colorectal Cancer Congress; Naples, FL, October 2006
|
Gupta, Manisha
|
|
2006
|
6 |
4 |
p. 258-260
3 p.
|
artikel
|
| 4 |
Novel Targets for Anticancer Treatment Development in Colorectal Cancer
|
Macarulla, Teresa
|
|
2006
|
6 |
4 |
p. 265-272
8 p.
|
artikel
|
| 5 |
Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine Therapy
|
Mercier, Cédric
|
|
2006
|
6 |
4 |
p. 288-296
9 p.
|
artikel
|
| 6 |
Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count
|
Michael, Michael
|
|
2006
|
6 |
4 |
p. 297-304
8 p.
|
artikel
|
| 7 |
Selected Clinical Trials in Colorectal Cancer
|
|
|
2006
|
6 |
4 |
p. 312-
1 p.
|
artikel
|
| 8 |
2006 - The Year in Review
|
Chu, Edward
|
|
2006
|
6 |
4 |
p. 256-257
2 p.
|
artikel
|
| 9 |
Xeloda® in Adjuvant Colon Cancer Therapy (X-ACT) Trial: Overview of Efficacy, Safety, and Cost-Effectiveness
|
Twelves, Chris J.
|
|
2006
|
6 |
4 |
p. 278-287
10 p.
|
artikel
|
Tijdschrift beschrijving